Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery
Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery
Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.
Material and Methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.
Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p < 0.001).
No antiglaucoma medication was required in 19 eyes 3 months after surgery, in 19 eyes 6 months after surgery, 19 eyes 12 months after surgery, 16 eyes 18 months after surgery and 15 eyes 24 months after surgery. One eye (5.26%) required monotherapy 18 months after surgery, and 2 eyes (10.52%) 24 months after surgery. Dual combination therapy was required 18 months after surgery in 2 eyes (10.52%) and 24 months after surgery in 2 eyes (10.52%). In the early postoperative period we found a loose conjunctival suture in 3 eyes, which was followed by resuturing in 1 eye. In the late postoperative period we found an obturated implant in 1 eye, which required implant replacement.
Conclusion: Our initial results suggest that the PRESERFLO™ MicroShunt glaucoma implant is an effective surgical technique with minimal postoperative complications, resulting in a statistically significant reduction in average IOP and discontinuation or reduction of topical antiglaucoma medication for 2 years after surgery.
Keywords:
intraocular pressure – primary open-angle glaucoma – minimally invasive glaucoma surgery – Preserflo MicroShunt
Autoři:
Veronika Fialová 1,2; Martin Váša 1; Pavel Rozsíval 1,2,3; Jitka Kalinová 1,4; Jan Studnička 1,2,3
Působiště autorů:
VISUS, spol. s. r. o.
1; Medical Faculty of Charles University in Hradec Králové, Czech Republic
2; Department of Ophthalmology, University Hospital in Hradec Králové, Czech Republic
3; Department of Thomayer Hospital, Prague, Czech Republic
4
Vyšlo v časopise:
Čes. a slov. Oftal., 81, 2025, No. 4, p. 189-196
Kategorie:
Původní práce
doi:
https://doi.org/10.31348/2025/9
Souhrn
Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.
Material and Methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.
Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p < 0.001).
No antiglaucoma medication was required in 19 eyes 3 months after surgery, in 19 eyes 6 months after surgery, 19 eyes 12 months after surgery, 16 eyes 18 months after surgery and 15 eyes 24 months after surgery. One eye (5.26%) required monotherapy 18 months after surgery, and 2 eyes (10.52%) 24 months after surgery. Dual combination therapy was required 18 months after surgery in 2 eyes (10.52%) and 24 months after surgery in 2 eyes (10.52%). In the early postoperative period we found a loose conjunctival suture in 3 eyes, which was followed by resuturing in 1 eye. In the late postoperative period we found an obturated implant in 1 eye, which required implant replacement.
Conclusion: Our initial results suggest that the PRESERFLO™ MicroShunt glaucoma implant is an effective surgical technique with minimal postoperative complications, resulting in a statistically significant reduction in average IOP and discontinuation or reduction of topical antiglaucoma medication for 2 years after surgery.
Štítky
OftalmologieČlánek vyšel v časopise
Česká a slovenská oftalmologie
2025 Číslo 4
- Stillova choroba: vzácné a závažné systémové onemocnění
- Diagnostický algoritmus při podezření na syndrom periodické horečky
- Patofyziologie glaukomu
- Stillova choroba aneb systémová forma juvenilní idiopatické artritidy
- Kontaktní dermatitida očních víček
Nejčtenější v tomto čísle
- Easy Method of Pterygium Excision using Autologous Blood for Conjunctiva Autograft Fixation
- Treatment of Patients with Central Serous Chorioretinopathy using Navigated Laser Photocoagulation
- Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery
- Vessel density and retinal nerve fiber layer in pathological intraocular pressure
